Literature DB >> 25517746

Combination of RAF and MEK inhibition for the treatment of BRAF-mutated melanoma: feedback is not encouraged.

Paul B Chapman1, David B Solit2, Neal Rosen3.   

Abstract

In BRAF V600E melanoma patients, RAF inhibitor treatment causes a MEK-inhibitor-sensitive, RAF-inhibitor-resistant adaptive reactivation of ERK signaling. In clinical trials combining MEK and RAF inhibitors, therapeutic efficacy was modestly enhanced, suggesting the utility of inhibiting feedback-reactivated pathways. Strategies for optimally inhibiting ERK signaling should be explored.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25517746     DOI： 10.1016/j.ccell.2014.10.017

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


  21 in total

1.  Integrating Transcriptomic Data with Mechanistic Systems Pharmacology Models for Virtual Drug Combination Trials.

Authors:  Anne Marie Barrette; Mehdi Bouhaddou; Marc R Birtwistle
Journal:  ACS Chem Neurosci       Date:  2017-10-06       Impact factor: 4.418

2.  Synthetic Lethal Interaction of SHOC2 Depletion with MEK Inhibition in RAS-Driven Cancers.

Authors:  Rita Sulahian; Jason J Kwon; Katherine H Walsh; Emma Pailler; Timothy L Bosse; Maneesha Thaker; Diego Almanza; Joshua M Dempster; Joshua Pan; Federica Piccioni; Nancy Dumont; Alfredo Gonzalez; Jonathan Rennhack; Behnam Nabet; John A Bachman; Amy Goodale; Yenarae Lee; Mukta Bagul; Rosy Liao; Adrija Navarro; Tina L Yuan; Raymond W S Ng; Srivatsan Raghavan; Nathanael S Gray; Aviad Tsherniak; Francisca Vazquez; David E Root; Ari J Firestone; Jeff Settleman; William C Hahn; Andrew J Aguirre
Journal:  Cell Rep       Date:  2019-10-01       Impact factor: 9.423

3.  Targeting BMK1 Impairs the Drug Resistance to Combined Inhibition of BRAF and MEK1/2 in Melanoma.

Authors:  Chengli Song; Lina Wang; Qiang Xu; Kai Wang; Dan Xie; Zhe Yu; Kui Jiang; Lujian Liao; John R Yates; Jiing-Dwan Lee; Qingkai Yang
Journal:  Sci Rep       Date:  2017-04-07       Impact factor: 4.379

4.  RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer.

Authors:  Gorjan Hrustanovic; Victor Olivas; Evangelos Pazarentzos; Asmin Tulpule; Saurabh Asthana; Collin M Blakely; Ross A Okimoto; Luping Lin; Dana S Neel; Amit Sabnis; Jennifer Flanagan; Elton Chan; Marileila Varella-Garcia; Dara L Aisner; Aria Vaishnavi; Sai-Hong I Ou; Eric A Collisson; Eiki Ichihara; Philip C Mack; Christine M Lovly; Niki Karachaliou; Rafael Rosell; Jonathan W Riess; Robert C Doebele; Trever G Bivona
Journal:  Nat Med       Date:  2015-08-24       Impact factor: 53.440

Review 5.  RAS, wanted dead or alive: Advances in targeting RAS mutant cancers.

Authors:  Clint A Stalnecker; Channing J Der
Journal:  Sci Signal       Date:  2020-03-24       Impact factor: 8.192

6.  Receptor-Driven ERK Pulses Reconfigure MAPK Signaling and Enable Persistence of Drug-Adapted BRAF-Mutant Melanoma Cells.

Authors:  Luca Gerosa; Christopher Chidley; Fabian Fröhlich; Gabriela Sanchez; Sang Kyun Lim; Jeremy Muhlich; Jia-Yun Chen; Sreeram Vallabhaneni; Gregory J Baker; Denis Schapiro; Mariya I Atanasova; Lily A Chylek; Tujin Shi; Lian Yi; Carrie D Nicora; Allison Claas; Thomas S C Ng; Rainer H Kohler; Douglas A Lauffenburger; Ralph Weissleder; Miles A Miller; Wei-Jun Qian; H Steven Wiley; Peter K Sorger
Journal:  Cell Syst       Date:  2020-10-27       Impact factor: 10.304

7.  Therapeutic efficacy of combined BRAF and MEK inhibition in metastatic melanoma: a comprehensive network meta-analysis of randomized controlled trials.

Authors:  Ruiqin Mai; Songxia Zhou; Weixiang Zhong; Siming Rong; Zhichao Cong; Yunxian Li; Qizhi Xie; Huanming Chen; Xiaoyun Li; Shuhui Liu; Yabin Cheng; Yuanshen Huang; Youwen Zhou; Guohong Zhang
Journal:  Oncotarget       Date:  2015-09-29

8.  Combination of antibodies directed against different ErbB3 surface epitopes prevents the establishment of resistance to BRAF/MEK inhibitors in melanoma.

Authors:  Luigi Fattore; Debora Malpicci; Emanuele Marra; Francesca Belleudi; Alessia Noto; Claudia De Vitis; Maria Elena Pisanu; Pierpaolo Coluccia; Rosa Camerlingo; Giuseppe Roscilli; Antoni Ribas; Arianna Di Napoli; Maria Rosaria Torrisi; Luigi Aurisicchio; Paolo Antonio Ascierto; Rita Mancini; Gennaro Ciliberto
Journal:  Oncotarget       Date:  2015-09-22

9.  Targeted next-generation sequencing reveals high frequency of mutations in epigenetic regulators across treatment-naïve patient melanomas.

Authors:  Jonathan J Lee; Lynette M Sholl; Neal I Lindeman; Scott R Granter; Alvaro C Laga; Priyanka Shivdasani; Gary Chin; Jason J Luke; Patrick A Ott; F Stephen Hodi; Martin C Mihm; Jennifer Y Lin; Andrew E Werchniak; Harley A Haynes; Nancy Bailey; Robert Liu; George F Murphy; Christine G Lian
Journal:  Clin Epigenetics       Date:  2015-06-09       Impact factor: 6.551

10.  Combinatorial drug screening and molecular profiling reveal diverse mechanisms of intrinsic and adaptive resistance to BRAF inhibition in V600E BRAF mutant melanomas.

Authors:  Devin G Roller; Brian Capaldo; Stefan Bekiranov; Aaron J Mackey; Mark R Conaway; Emanuel F Petricoin; Daniel Gioeli; Michael J Weber
Journal:  Oncotarget       Date:  2016-01-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.